News & Commentary
A proposal by the Accreditation Council for Graduate Medical Examination (ACGME), an organization that oversees the training of young physicians, would allow first-year doctors (or interns) to work 24-hour shifts, eight hours longer than they’re currently permitted to work.

This is one of those anecdotes that make you stop and think, and then worry. A woman died in September in Reno, Nev., of a superbug that resisted 26 different kinds of antibiotics, the CDC reported yesterday in its Morbidity and Mortality Weekly Report.

News & Commentary
Deloitte asked 600 primary care and specialty physicians how far along they are in transitioning from a volume- to a value-based system of care. Only 3% of health systems and medical groups provide more than half of all care under value-based contracts.

Cigna has jumped into the ongoing EpiPen controversy with both feet with its decision to not cover the brand version of the product without first giving prior authorization, STAT reports.

Ted Slafsky, MPP & Robert Chapman, MD

In an era of rapidly escalating prices, the 340B drug discount program remains one of the few checks to keep medicine and medical care accessible to the underserved. Contrary to the recent column, "Payers Must Develop Strategies To Overcome 340B Hurdles," it is not being exploited by participating hospitals.

If it were, where exactly is the money?

Zachary Hafner

Zachary Hafner
Advisory Board

If you’re still bickering over rate hikes and contract minutiae, then you’re out of step with the new health care economy. In progressive markets, savvy payers and providers that work together rather than constantly bumping heads are pulling ahead at the expense of slow movers and status quo players.

President-elect Donald Trump made his feelings about Obamacare crystal clear yesterday, telling the New York Times that he wants the ACA repealed and replaced quickly—as in very quickly. As in, do it in two weeks, Congress.

Speed seems to be the theme these days when it comes to approval of medications. The first step is knocking down the obstacles that delay getting new, potentially life-saving medications to the market. That’s especially true in oncology.

Q&A: The View From the Intermountain Top
Interview by Peter Wehrwein
Marc Harrison, MD
The new president and CEO of Intermountain looks ahead to the Utah system becoming a referral center and says last year’s net operating margin can be chalked up to an implementation of an electronic medical record system.
What To Expect in 2017: Managed Care Year in Preview
Jan Greene

Amazon Echo

Getting older people to bring a new technology into their homes has been more difficult than expected. Nevertheless, the tech industry continues to work on new options, and there are some intriguing possibilities on the horizon for 2017 and beyond.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.